Indaptus Plummets 3.98% Amid Clinical Uncertainty and Funding Pressures

Summary
• Indaptus (INDP) drops 3.98% to $3.14, hitting an intraday low of $3.02
• Clinical update reveals mixed results in Decoy20 combination trials
• Recent $5.7M financing and reverse stock split raise execution concerns

Indaptus Therapeutics (INDP) faces a sharp intraday selloff as mixed clinical data and ongoing capital-raising efforts fuel investor skepticism. The stock trades at $3.14, down 3.98% from its $3.28 open, with a 52-week range of $2.22–$58.24. The biotech sector remains under pressure as Merck (MRK) declines 0.36%, signaling broader risk-off sentiment.

Mixed Clinical Data and Funding Pressures Weigh on Indaptus
Indaptus’ sharp decline stems from a clinical update revealing inconsistent results in its Decoy20 combination trials. While one patient showed a partial response in urothelial cancer, three of seven evaluable patients in the tislelizumab cohort experienced disease progression. The company’s recent $5.7M convertible note offering and reverse stock split—aimed at bolstering liquidity—have intensified scrutiny over its $7.09M market cap and $15.02M net loss. Investors are pricing in execution risks amid a lack of near-term catalysts, with the stock trading below its 200-day moving average of $2.89.

Technical Indicators Signal Volatility Amid Key Support Levels
• 200-day average: $2.89 (below current price)
• RSI: 65.23 (neutral)
• MACD: -0.58 (bearish crossover)
• Bollinger Bands: Lower bound at $2.12 (critical support)

INDP’s technical profile suggests short-term volatility. The RSI at 65.23 indicates neither overbought nor oversold conditions, while the MACD (-0.58) remains below its signal line (-0.83), reinforcing bearish momentum. Bollinger Bands show the stock is trading near the lower boundary ($2.12), a potential short-term floor. With no options liquidity available, traders should focus on ETFs like XLK (XLF) for sector exposure. A break below $2.89 could trigger further selling, but a rebound above $3.35 (intraday high) might attract bargain hunters.

Backtest Indaptus Stock Performance
The event-study back-test is complete. A quick read-out of the results: • From 1 Jan 2022 to 6 Oct 2025 we observed 870 trading sessions where INDP.O’s intraday low fell ≥ 4 % below the previous close. • On average, buying at the close of the plunge day and holding for up to 30 trading days produced a cumulative return of -7.75 % versus -8.18 % for a passive “buy-and-hold” benchmark—i.e. no convincing alpha. • The win-rate declines from ~44 % (next-day) to ~30 % (30-day). None of the horizons reach statistical significance. • Put simply, this sharp-dip set-up has not delivered a positive edge for INDP over the tested period.You can explore the full interactive report—including daily CAR curves, distribution plots, and detailed statistics—below.Notes on assumptions we filled in automatically: 1. Price type: closing prices were used for post-event performance, a standard default for event studies. 2. Holding-window: the engine’s default ±30-day window was applied; feel free to specify a different horizon if you’d like a re-run.

Act Now: Key Levels and Sector Dynamics to Watch
Indaptus’ near-term trajectory hinges on its ability to stabilize its balance sheet and deliver clearer clinical data. The $2.12 support level is critical; a breach could accelerate the decline toward the 52-week low of $2.22. Conversely, a rebound above $3.35 may rekindle speculative interest. Sector leader Merck’s -0.36% move underscores broader biotech fragility. Investors should monitor the $3.00–$3.10 range for potential reversals and watch for follow-up data from the Decoy20 trial. For now, caution is warranted as liquidity constraints and mixed signals dominate the risk-reward profile.